CAR T-Cells will surely be the hot topic both on a clinical and commercial standpoint. More to follow!

More advanced results expected for LAG-3 inhibitors, STING agonists, TLR9 agonists along with other promising early stage developments.

As PD-1 inhibitors make inroads into many more segments, combinations with approved chemotherapies, PARP inhibitors and TKIs will raise the bars